An international, randomised, open label trial comparing a rituximab based regimen and a standard cyclophosphamide/azathioprine based regimen in the treatment of active 'generalised' ANCA associated vasculitis.

Trial Profile

An international, randomised, open label trial comparing a rituximab based regimen and a standard cyclophosphamide/azathioprine based regimen in the treatment of active 'generalised' ANCA associated vasculitis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RITUXVAS
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top